Samarth Kulkarni
2021
Compensation breakdown
Non-Equity Incentive Plan | $587,925 |
---|---|
Option Awards | $10,954,947 |
Salary | $670,000 |
Stock Awards | $4,819,680 |
Other | $4,463 |
Total | $17,037,015 |
Kulkarni received $11M in option awards, accounting for 64% of the total pay in 2021.
Kulkarni also received $587.9K in non-equity incentive plan, $670K in salary, $4.8M in stock awards and $4.5K in other compensation.
Rankings
In 2021, Samarth Kulkarni's compensation ranked 428th out of 12,412 executives tracked by ExecPay. In other words, Kulkarni earned more than 96.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 428 | 97th |
Manufacturing | 134 | 98th |
Chemicals And Allied Products | 40 | 98th |
Drugs | 35 | 98th |
Biological Products, Except Diagnostic Substances | 15 | 97th |
Kulkarni's colleagues
We found five more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2021.
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
James Kasinger
CRISPR Therapeutics AG
General Counsel
2021
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
News
April 25, 2022
April 28, 2021
April 24, 2020
April 30, 2019